Back to Search

CARA HEUSER, MD

MD

Maternal & Fetal Medicine Physician

NPI: 1568674208IndividualAccepts Medicare

Specialties, Licenses & Credentials

Maternal & Fetal Medicine PhysicianPrimary

Obstetrics & Gynecology — Maternal & Fetal Medicine

Code: 207VM0101X

6885456-1205(UT)

CMS Specialties

PrimaryOBSTETRICS/GYNECOLOGY

Education

UNIVERSITY OF VIRGINIA SCHOOL OF MEDICINE

Class of 2004

Research & Publications (20)

A clinical and biological comparison between malignant mixed müllerian tumors and grade 3 endometrioid endometrial carcinomas.
PMID 19396006·Int J Gynecol Cancer·2009
4-observational
Bait acceptability for delivery of oral rabies vaccine to free-ranging dogs on the Navajo and Hopi Nations.
PMID 18634474·Dev Biol (Basel)·2008
7-preclinical
T cell activation by antibody-like immunoreceptors: the position of the binding epitope within the target molecule determines the efficiency of activation of redirected T cells.
PMID 17372024·J Immunol·2007
8-other
Does the addition of glutamine to enteral feeds affect patient mortality?
PMID 16276173·Crit Care Med·2005
3-trial
Predictors of suboptimal surgical cytoreduction in women treated with initial cytoreductive surgery for advanced stage epithelial ovarian cancer.
PMID 16098898·Am J Obstet Gynecol·2005
8-other
Simultaneous targeting of IL2 and IL12 to Hodgkin's lymphoma cells enhances activation of resting NK cells and tumor cell lysis.
PMID 15688386·Int J Cancer·2005
8-other
T cell activation by antibody-like immunoreceptors: increase in affinity of the single-chain fragment domain above threshold does not increase T cell activation against antigen-positive target cells but decreases selectivity.
PMID 15585893·J Immunol·2004
4-observational
Anti-CD30-scFv-Fc-IL-2 antibody-cytokine fusion protein that induces resting NK cells to highly efficient cytolysis of Hodgkin's lymphoma derived tumour cells.
PMID 15095304·Int J Cancer·2004
7-preclinical
An anti-MUC1-antibody-interleukin-2 fusion protein that activates resting NK cells to lysis of MUC1-positive tumour cells.
PMID 12966437·Br J Cancer·2003
8-other
T-cell activation by recombinant immunoreceptors: impact of the intracellular signalling domain on the stability of receptor expression and antigen-specific activation of grafted T cells.
PMID 12900755·Gene Ther·2003
8-other
Immune response manipulation: recombinant immunoreceptors endow T-cells with predefined specificity.
PMID 12871185·Curr Pharm Des·2003
6-review
Anti-CD30-IL-12 antibody-cytokine fusion protein that induces IFN-gamma secretion of T cells and NK cell-mediated lysis of Hodgkin's lymphoma-derived tumor cells.
PMID 12845650·Int J Cancer·2003
7-preclinical
Images in cardiovascular medicine. Unusual biventricular thrombus formation in acute myeloid leukemia and factor V Leiden mutation.
PMID 12732597·Circulation·2003
5-case
Generation, expression, and monitoring of recombinant immune receptors for use in cellular immunotherapy.
PMID 12412486·Methods Mol Biol·2003
7-preclinical
The recombinant T cell receptor strategy: insights into structure and function of recombinant immunoreceptors on the way towards an optimal receptor design for cellular immunotherapy.
PMID 12109217·Curr Gene Ther·2002
6-review
Tuning tumor-specific T-cell activation: a matter of costimulation?
PMID 12102744·Trends Immunol·2002
6-review
Tumor-specific T cell activation by recombinant immunoreceptors: CD3 zeta signaling and CD28 costimulation are simultaneously required for efficient IL-2 secretion and can be integrated into one combined CD28/CD3 zeta signaling receptor molecule.
PMID 11714771·J Immunol·2001
8-other
CD4+ T cells engrafted with a recombinant immunoreceptor efficiently lyse target cells in a MHC antigen- and Fas-independent fashion.
PMID 11441120·J Immunol·2001
8-other
T cells engrafted with a recombinant anti-CD30 receptor target autologous CD30(+) cutaneous lymphoma cells.
PMID 11423937·Gene Ther·2001
5-case
T-cell activation by recombinant receptors: CD28 costimulation is required for interleukin 2 secretion and receptor-mediated T-cell proliferation but does not affect receptor-mediated target cell lysis.
PMID 11280755·Cancer Res·2001
7-preclinical

Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.

Contact & Hours

Address
5121 COTTONWOOD ST, SUITE 100
SALT LAKE CITY, UT 84107

Location

Practice Location

5121 COTTONWOOD ST, SALT LAKE CITY, UT
(801) 507-7400

Quick Facts

NPI
1568674208
Entity Type
Individual
Gender
Female
Medicare
Accepted
Specialties
1
Locations
1
Years in Practice
22
Publications
20

Are you this provider?

Claim Your Profile